Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis

Semin Hematol. 2023 Mar;60(2):113-117. doi: 10.1053/j.seminhematol.2023.03.002. Epub 2023 Mar 29.

Abstract

Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis, prognosis, and therapy of AL amyloidosis associated with Waldenström macroglobulinemia (WM). Since significant advances have been made in the management of AL amyloidosis an update for this rare disease associated with WM was necessary. The key recommendations from IWWM-11 CP6 included: (1) The need to improve the diagnostic process by recognizing red flags and using biomarkers and imaging; (2) The essential tests for appropriate workup; (3) The diagnostic flowchart, including mandatory amyloid typing, that improves the differential diagnosis with transthyretin amyloidosis; (4) Criteria for therapy response assessment; (5) State of the art of the treatment including therapy of wild type transthyretin amyloidosis associated with WM.

Keywords: AL amyloidosis; Diagnostic criteria; Response assessment; Therapy; Waldenström macroglobulinemia.

MeSH terms

  • Amyloid Neuropathies, Familial* / complications
  • Consensus
  • Humans
  • Immunoglobulin Light-chain Amyloidosis* / complications
  • Immunoglobulin Light-chain Amyloidosis* / diagnosis
  • Immunoglobulin Light-chain Amyloidosis* / therapy
  • Waldenstrom Macroglobulinemia* / complications
  • Waldenstrom Macroglobulinemia* / diagnosis
  • Waldenstrom Macroglobulinemia* / therapy

Supplementary concepts

  • Amyloidosis, Hereditary, Transthyretin-Related